Lupin gets USFDA nod for Sevelamer Hydrochloride tablets for treating chronic kidney disease

Lupin gets USFDA nod for Sevelamer Hydrochloride tablets for treating chronic kidney disease

Apurva Joshi
/ Categories: Trending, Mindshare, DSIJ News

Lupin Limited has received approval for its Sevelamer Hydrochloride tablets, 400 mg & 800 mg from United States Food & Drug Administration (USFDA) to market a generic equivalent of Renagel tablets, 400 mg & 800 mg, of Genzyme Corporation. The product will be manufactured at Lupin’s facility in Nagpur (Maharashtra). 

Sevelamer Hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. 

As per IQVIA MAT’s data for March 2021, Sevelamer Hydrochloride tablets had estimated annual sales of USD 80 million in the US. 

Also, this week, the company’s UK subsidiary had received approval from Medicines & Healthcare products Regulatory Agency (MHRA) to market Luforbec 100/6 µg pressurised metered-dose inhaler (pMDI), the first-branded generic of Fostair 100/6 µg pMDI. It is indicated for regular treatment of asthma as well as for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD). 

Lupin is an innovation-led transnational pharmaceutical company, which develops & commercialises a wide range of branded and generic formulations, biotechnology products along with APIs in over 100 markets in the US, India, South Africa, and across Asia Pacific (APAC), Latin America (LATAM), Europe & Middle-East regions. 

On Thursday, the stock of Lupin closed 1.21 per cent lower at Rs 1,162.65 from its previous close of Rs 1,176.85 on BSE. 

Previous Article Know more about Meme stock and why investors prefer investing in them
Next Article Twist in the tale of Himadri Speciality Chemical stock price surge
Rate this article:
4.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR